Clinical Trial Update: Safety and Efficacy of Basiliximab, Delayed Dose Tacrolimus Plus ECMPA (Enteric Coated Mycophenolic Acid) Following Liver Transplantation [Phase 4]

View source ↗

Summary

Phase 4 trial update on safety and efficacy of basiliximab with delayed-dose tacrolimus and ECMPA after liver transplantation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Transplantation

Drugs mentioned

• Basiliximab (basiliximab)
• Enteric Coated Mycophenolic Acid (ECMPA) (mycophenolic acid enteric-coated formulation)
• Tacrolimus (delayed dose) (tacrolimus)

Snippet

Sponsor: University of California, Los Angeles | Conditions: Liver Transplantation | Phase 4 | Status: COMPLETED | Results posted: 2022-09-29